

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/086,181	02/26/2002	Ruth Gimeno	MNI-220	8227	
30405	7590 05/09/2005		EXAMINER		
MILLENNIUM PHARMACEUTICALS, INC. 40 Landsdowne Street			MAYER, SUZANNE MARIE		
	GE, MA 02139		ART UNIT	PAPER NUMBER	
	,		1653	-	
			DATE MAILED: 05/09/2005	5 .	

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No.   Application No.   Application No.   GIMENO ET AL					
Examiner  Suzanne M. Mayer, Ph.D.  - The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply  A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE of FIHS COMMUNICATION.  Edenations of time may be available under the provisions of 37 CPR 1.13(a). In no event, however, may a reply be timely filed with the SIX (9) MONTHS from the maning date of the communication.  If NO period for reply is appoilted above, the maninum shahlarly period will apply and will again 81X (8) MONTHS from the maninum distribution.  If NO period for reply is appoilted above, the maninum shahlarly period will apply and will again 81X (8) MONTHS from the malling date of this communication.  If NO period for reply is appoilted above, the maninum shahlarly period will apply and will again 81X (8) MONTHS from the malling date of this communication.  Parties to reprove which the size or communication of the shahlarly period will apply and will again 81X (8) MONTHS from the malling date of this communication.  Parties to reprove which the size or communication of the malling date of this communication.  Parties to reprove the provision of the size of the malling date of this communication.  Parties to reprove the provision of the malling date of this communication.  Parties to reprove the provision of the malling date of this communication.  Parties to reprove the provision of the malling date of this communication.  Parties to reprove the provision of the malling date of this communication.  Parties to reprove the provision of the malling date of this communication.  Parties to reprove the provision of the malling date of this communication.  Parties to reprove the provision of the malling date of this communication.  Parties to reprove the provision of the malling date of the communication.  Parties to reprove the provision of the			Application No.	Applicant(s)	
Suzanne M. Mayer, Ph.D. 1653  Suzanne M. Mayer, Ph.D. 1653  A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  If the period for reply specified above is test ban titiny (20) days, as tepty be timely filed to the previous date of the previous part of TOPR 1.136(a). In no event, however, may a reply be timely filed to the previous date of the communication. If the period for reply specified above is test ban titiny (20) days, as tepty within the statisticy minimum of this (20) days will be considered timely.  If the period for reply specified above is test ban titine and titiny (20) days, as tepty within the statisticy minimum of this (20) days will be considered timely.  If the period for reply specified above is test ban the communication.  Any reply reviewed by the Office later than these months after the mailing date of this communication, even if timely field, may reduce any search part test and judicious for the communication.  Application is FINAL.  2b) This action is roundition of reliowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims  4) Claim(s) 1-72 is/are pending in the application.  4) Claim(s) is/are allowed.  5) Claim(s) is/are allowed.  5) Claim(s) is/are allowed.  6) Claim(s) is/are objected to by the Examiner.  Application Papers  9) The specification is objected to by the Examiner.  Application Papers  9) The specification is objected to by the Examiner.  Application Papers  9) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some *O  None of:  1 Certified copies of the priority documents have been received in Application No.  3 (Cepties of the certified copies of the priority documents have been received in this National Stage application fro	Office Action Summan		10/086,181	GIMENO ET AL.	
The MALING DATE of this communication appears on the cover sheet with the correspondence address → Period for Reply  A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  Editacions of time may be available under the procession of 37 CPR 1.136(a). In no event, however, may a reply be timely filed where SX (5) MCNTHS from the realing date of this communication.  If No pariod for reply is specified above, the maximum abstrator period within the stutions replained in the SX (5) MCNTHS from the realing date of this communication.  Failure to reply voilin the set or extended panied for reply voil. The set of extended panied show the maximum abstrator period will apply and will expect \$(6) (AMOTHS from the mailing date of this communication.  Failure to reply voilin the set of extended panied for reply voil. The set of extended panied show the maximum abstrator period will apply and will expect \$(6) (AMOTHS from the mailing date of this communication.  Failure to reply voilin the set of extended panied for reply voilin the studence of the communication.  Failure to reply voilin the set of extended panied show the maximum and part of the communication.  Failure to reply voilin the set of extended panied show the mailing date of this communication.  Failure to reply voilin the set of extended panied show the maximum and panied to the communication.  Failure to reply voilin the set of extended panied show the maximum and panied to the communication.  Failure to reply voilin the set of extended panied show the maximum and panied show the set of extended panied to the communication.  Failure to reply voilin the set of extended panied show the set of		Onice Action Summary	Examiner	Art Unit	
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE <u>1</u> MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  Edurations of time may be available under the grovisions of 37 CFR 1.13(e), in no event, however, may a reply be limity filled.  Eduration of the properties of the provisions of 37 CFR 1.13(e), in no event, however, may a reply be limity filled.  Eduration of the properties of the provisions of 37 CFR 1.13(e), in no event, however, may a reply be limity filled.  Eduration of the provision of the provisions of 37 CFR 1.13(e), in no event, however, may a reply be limit to set or control and provide for reply in specified above, the maximum statutory period vital paply and valid expire SIX (b) MONTH's from the mailing date of this communication. Provided by the Office later than three mailing date of this communication, even if timely filled, may reduce any eventure placetis than adjustment. See 27 CFR 1.10(de).  Status  1) Responsive to communication(s) filled on			_		
THE MAILING DATE OF THIS COMMUNICATION.  Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after 50k (6) MONTHS from the mailing date of this communication.  If the period for reply specified above is less than thin (70) days, a reply visible the statutory minimum of thin (70) days, a valid to communication.  Failure to reply velible the order of the reply velible the statutory minimum of thin (70) days, a valid into your status of the communication is the status of the communication to the com			on appears on the cover sheet w	ith the correspondence address	
1) Responsive to communication(s) filed on	THE I - External after - If the - If NO - Failu Any r	MAILING DATE OF THIS COMMUNICAT nsions of time may be available under the provisions of 37 SIX (6) MONTHS from the mailing date of this communicate period for reply specified above is less than thirty (30) day period for reply is specified above, the maximum statuton re to reply within the set or extended period for reply will, the ply received by the Office later than three months after the	FION.  CFR 1.136(a). In no event, however, may a tion.  Is, a reply within the statutory minimum of this y period will apply and will expire SIX (6) MOI by statute, cause the application to become A	reply be timely filed  ty (30) days will be considered timely.  NTHS from the mailing date of this communication.  BANDONED (35 U.S.C. § 133).	
2a)  This action is FINAL. 2b)  This action is non-final.  3)  Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims  4)  Claim(s) 1-72 is/are pending in the application.  4a) Of the above claim(s)  is/are withdrawn from consideration.  5)  Claim(s)  is/are allowed.  6)  Claim(s)  is/are rejected.  7)  Claim(s)  is/are objected to.  8)  Claim(s) 1-72 are subject to restriction and/or election requirement.  Application Papers  9)  The specification is objected to by the Examiner.  10)  The drawing(s) filed on  is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.  Priority under 35 U.S.C. § 119  12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some c) None of:  1.  Certified copies of the priority documents have been received in Application No.  3.  Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.	Status				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims  4) Claim(s) 1-72 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) is/are objected to. 7) Claim(s) is/are objected to. 8) Claim(s) 1-72 are subject to restriction and/or election requirement.  Application Papers  9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) cacepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.  Priority under 35 U.S.C. § 119  12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.	1) 🗌	Responsive to communication(s) filed or	ı		
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims  4)  Claim(s) 1-72 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration.  5)  Claim(s) is/are allowed. 6)  Claim(s) is/are objected to. 8)  Claim(s) is/are objected to. 8)  Claim(s) 1-72 are subject to restriction and/or election requirement.  Application Papers  9)  The specification is objected to by the Examiner.  10)  The drawing(s) filed on is/are: a) cacepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.  Priority under 35 U.S.C. § 119  12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.	2a) <u></u> □	This action is <b>FINAL</b> . 2b)	☑ This action is non-final.		
4) Claim(s) 1-72 is/are pending in the application.  4a) Of the above claim(s)  is/are withdrawn from consideration.  5) Claim(s)  is/are allowed.  6) Claim(s)  is/are rejected.  7) Claim(s)  is/are objected to.  8) Claim(s) 1-72 are subject to restriction and/or election requirement.  Application Papers  9) The specification is objected to by the Examiner.  10) The drawing(s) filed on  is/are: a) cocepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.  Priority under 35 U.S.C. § 119  12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No.  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.	3) 🗌		•	• *	
4a) Of the above claim(s) is/are withdrawn from consideration.  5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) is/are objected to. 8) Claim(s) is/are subject to restriction and/or election requirement.  Application Papers  9) The specification is objected to by the Examiner.  10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.  Priority under 35 U.S.C. § 119  12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1 Certified copies of the priority documents have been received.  2 Certified copies of the priority documents have been received in Application No  3 Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.	Dispositi	on of Claims			
9) The specification is objected to by the Examiner.  10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.  Priority under 35 U.S.C. § 119  12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  Attachment(s)  1) Notice of References Cited (PTO-892)	5)	4a) Of the above claim(s) is/are w Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to.	ithdrawn from consideration.		
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.  Priority under 35 U.S.C. § 119  12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No.  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  Attachment(s)  1) Notice of References Cited (PTO-892)	Applicati	on Papers			
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.  Priority under 35 U.S.C. § 119  12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  Attachment(s)  1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)	9) 🗌	The specification is objected to by the Ex	aminer.		
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.  Priority under 35 U.S.C. § 119  12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No.  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  Attachment(s)  1) Notice of References Cited (PTO-892)	10)	The drawing(s) filed on is/are: a)[	accepted or b) objected to	by the Examiner.	
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.  Priority under 35 U.S.C. § 119  12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No.  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  Attachment(s)  1) Notice of References Cited (PTO-892)		Applicant may not request that any objection	to the drawing(s) be held in abeya	nce. See 37 CFR 1.85(a).	
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No.  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  Attachment(s)  1) Notice of References Cited (PTO-892)	11)		•	· · · · · · · · · · · · · · · · · · ·	′
a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  Attachment(s)  1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)	Priority u	ınder 35 U.S.C. § 119			
1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)	a)[	All b) Some * c) None of:  1. Certified copies of the priority doc  2. Certified copies of the priority doc  3. Copies of the certified copies of the application from the International	uments have been received. uments have been received in A le priority documents have beer Bureau (PCT Rule 17.2(a)).	Application No  received in this National Stage	
1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)	Attachmen	t(s)			
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  Paper No(s)/Mail Date  5) Notice of Informal Patent Application (PTO-152)  Cher:	1)  Notic 2)  Notic 3)  Inforr	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-9 nation Disclosure Statement(s) (PTO-1449 or PTO	(48) Paper No. (∕SB/08) 5) ☐ Notice of	s)/Mail Date nformal Patent Application (PTO-152)	

Art Unit: 1653

## **DETAILED ACTION**

1. The examiner and location of your application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Art Unit 1653.

- 2. Claims 1-72 are pending in this application.
- 3. It has been determined that the prior restriction requirement of November 29, 2004 was incomplete, hence the need for this second restriction requirement. Any inconvenience is regretted.

## Election/Restrictions

- 4. Prior to setting forth the restriction requirement, it is pointed out that the claims are drawn to patentably distinct methods. The methods and agents/products used in the methods, rely upon small molecules, gene therapy vectors, antibodies, anti-sense DNA, ribozymes, DNA molecules or polypeptide molecules used to treat or assay various molecules that are drawn to different diseases and such as aberrant lipogenesis, aberrant lipolysis, obesity, diabetes etc., thereto which differ in structure and modes of action to such an extent and require non-coextensive searches to such an extent that they are considered separately patentable. Therefore, the restriction will be set forth for each of the various groups, irrespective of the format of the claims, because these are not proper species. Applicant is invited to clearly elect a single Group as it reads on a particular method, the modulators used in the method and the disease treated by the method. The Groups set forth below appear to read on the claims as currently recited, but may be subject to further Restriction and/or species election depending on the claimed recitation.
- 5. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1-9 and 13-20, drawn to a method of identifying a nucleic acid molecule associated with a metabolic disorder, classified in class 435, subclass 6.
  - II. Claims 10-12 and 21-23, drawn to a method of identifying a polypeptide associated with a metabolic disorder, classified in class 435, subclass 7.1.

Page 2

Art Unit: 1653

III. Claim 24, drawn to a method for identifying a compound capable of treating a metabolic disorder caused by aberrant 14273 nucleic acid expression, classified in class 435, subclass 6.

Page 3

- IV. Claims 24 and 29, drawn to a method for identifying a compound capable of treating a metabolic disorder caused by aberrant 14273 polypeptide activity, classified in class 435, subclass 7.1.
- Note: If any of groups III-IV is elected, applicant is required to select a specific metabolic disorder to be treated selected from one of claims 25-28 that will be examined along with the elected group
- V. Claims 30, 31 and 36, drawn to a method of treating a subject having a metabolic disorder by administering a 14273 modulator where the modulator is a small molecule, classified in class 424, subclass 12.
- VI. Claims 30, 36 and 37, drawn to a method of treating a subject having a metabolic disorder by administering a 14273 modulator where the modulator is a gene therapy vector, classified in class 514, subclass 44.
- VII. Claims 30, 36, 38 and 39, drawn to a method of treating a subject having a metabolic disorder by administering a 14273 modulator where the modulator is an anti-14273 antibody that can modulate a 14273 polypeptide activity, classified in class 424, subclass 130.1.
- VIII. Claims 30, 36, 38 and 40-42, drawn to a method of treating a subject having a metabolic disorder by administering a 14273 modulator where the modulator is a 14273 polypeptide that can modulate a 14273 polypeptide activity, classified in class 514, subclass 12.

Art Unit: 1653

- IX. Claims 30, 36, 43 and 44, drawn to a method of treating a subject having a metabolic disorder by administering a 14273 modulator where the modulator is a 14273 anti-sense DNA molecule that can modulate 14273 nucleotide expression, classified in class 514, subclass 44.
- X. Claims 30, 36, 43 and 45, drawn to a method of treating a subject having a metabolic disorder by administering a 14273 modulator where the modulator is a ribozyme that can modulate 14273 nucleotide expression, classified in class 514, subclass 44.
- XI. Claims 30, 36, 43 and 46-48, drawn to a method of treating a subject having a metabolic disorder by administering a 14273 modulator where the modulator is a nucleic acid that can modulate 14273 nucleotide expression, classified in class 514, subclass 44.
- Note: If any of groups V-XI is elected, applicant is required to select a specific metabolic disorder to be treated selected from one of claims 32-35 that will be examined along with the elected group
- XII. Claim 49, drawn to a method for identifying a compound that can modulate an adipocyte activity by assaying the compound to test if it modulates the expression of a 14273 nucleic acid, classified in class 435, subclass 6.
- XIII. Claim 49, drawn to a method for identifying a compound that can modulate an adipocyte activity by assaying the compound to test if it modulates the expression of a 14273 polypeptide activity, classified in class 435, subclass 7.1.

Art Unit: 1653

- Note: If any of groups XII-XIII is elected, applicant is required to select a specific metabolic disorder to be treated selected from one of claims 50-52 that will be examined along with the elected group
- XIV. Claims 53-54, drawn to a method for modulating an adipocyte activity by contacting an adipocyte with a 14273 modulator, where the modulator is a small molecule, classified in class 514, subclass 1.
- XV. Claims 53, 58 and 59, drawn to a method for modulating an adipocyte activity by contacting an adipocyte with a 14273 modulator, where the modulator is an anti-14273 antibody that can modulate a 14273 polypeptide activity, classified in class 424, subclass 130.1.
- XVI. Claims 53, 58 and 60-62, drawn to a method for modulating an adipocyte activity by contacting an adipocyte with a 14273 modulator, where the modulator is a polypeptide that can modulate a 14273 polypeptide activity, classified in class 514, subclass 12.
- XVII. Claims 53, 63 and 64, drawn to a method for modulating an adipocyte activity by contacting an adipocyte with a 14273 modulator, where the modulator is an 14273 anti-sense DNA molecule that can modulate 14273 nucleic acid expression, classified in class 514, subclass 44.
- XVIII. Claims 53, 63 and 65, drawn to a method for modulating an adipocyte activity by contacting an adipocyte with a 14273 modulator, where the modulator is a ribozyme that can modulate 14273 nucleic acid expression, classified in class 514, subclass 44.

Page 6

XIX. Claims 53, 63 and 64, drawn to a method for modulating an adipocyte activity by contacting an adipocyte with a 14273 modulator, where the modulator is a DNA molecule that can modulate 14273 nucleic acid expression, classified in class 514, subclass 44.

- Note: If any of groups XIV-XIX is elected, applicant is required to select a specific metabolic disorder to be treated selected from one of claims 55-57 that will be examined along with the elected group.
- XX. Claim 69, drawn to a method of modulating glucose production in a cell, classified in class 435, subclass 7.1.
- XXI. Claim 70, drawn to a transgenic mouse, classified in class 800, subclass 18.
- XXII. Claim 71, drawn to a method of identifying a compound capable of treating a metabolic disorder by administering a compound to a transgenic mouse, classified in class 800, subclass 3.
- XXIII. Claim 72, drawn to an isolated cell, or purified preparation of cells from a transgenic mouse, classified in class 800, subclass 3.

The inventions are distinct, each from the other because of the following reasons:

6. Inventions I-XXIII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). Specifically I-XX are drawn to different methods. In the instant case the different inventions involve completely different methods from assaying nucleic acid expression (I) to assaying polypeptide activities (II), to methods used to treat subjects having a

Art Unit: 1653

metabolic disorder by administering proteins, DNA, antibodies, anti-sense DNA, ribozymes or gene therapy vectors. Thus the methods of treatment are drawn to completely different molecules that will have different modes of operation and action in the body. Furthermore, none of these molecules share a common structural feature and would thus require non-coextensive searches.

Groups XXI-XXIII are unrelated because they are drawn to a transgenic mouse, and methods of using a transgenic mouse to perform *in vivo* and *in vitro* testing. Thus the modes of operation and method steps will vary and the methods could be performed with a materially different transgenic animal such as a rabbit.

- 7. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.
- 8. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Suzanne M. Mayer, Ph.D. whose telephone number is 571-272-2924. The examiner can normally be reached on Monday to Friday, 8.30am to 5.00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached on 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1653

Page 8

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

SMM 30 April, 2005

ROBERT A. WAX
PRIMARY EXAMINER